Cure8 research brief
Why This Matters
A new molecular finding (PTPRK::RSPO3 fusion) in a serrated colorectal lesion from a person with ulcerative colitis may be relevant to understanding dysplasia and cancer pathways in IBD, and could prompt further study of serrated lesions in this population.
Who Should Pay Attention
Clinicians who perform surveillance colonoscopy for IBD, pathologists, researchers studying colorectal neoplasia and IBD-associated dysplasia, and patients with ulcerative colitis interested in colorectal cancer surveillance.
Study Snapshot
What To Know
The report describes a single rectal superficially serrated adenoma in a 57‑year‑old woman with longstanding ulcerative colitis. The lesion was removed by cold snare polypectomy after endoscopic detection and examined histologically and molecularly.
Pathology and testing: Histology showed superficially serrated epithelium with adenoma-like glands; immunohistochemistry supported serrated differentiation. Molecular analysis detected a KRAS Q61H mutation and an apparently novel PTPRK::RSPO3 fusion retaining RSPO3 coding sequence. Implications and limits: This is a single-case, hypothesis-generating report.
The authors state additional clinicopathological and molecular series are needed to determine whether superficially serrated adenomas in ulcerative colitis are incidental or represent a distinct IBD-associated pathway.
Keep In Mind
This is a single-case report posted as a preprint/posted content with abstract-level structured depth; findings are exploratory. It does not establish clinical risk or change surveillance recommendations. Additional larger studies are required to assess prevalence and significance of RSPO3 fusions in IBD-associated lesions.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.